Coronary heart disease
Conditions
Interventions
Control group:The control group received basic treatment: Drugs to improve prognosis, drugs to improve symptoms and other metabolic drugs.
Experimental Group:The experimental group used: Basic treatment + Changluo Tiaogan Dingsoul decoction
Sponsors
Affiliated Hospital of Shaanxi University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Patients with grade I to II angina pectoris who meet the diagnostic criteria for stable angina pectoris of CHD in western medicine and have at least 3 episodes of angina pectoris per week: (2) Electrocardiogram examination has one of the following: positive exercise test electrocardiogram: negative ordinary electrocardiogram, but the subject has a clear history of previous myocardial infarction, or coronary artery disease confirmed by coronary angiography (50% stenosis of any vessel) or myocardial radionuclide imaging: electrocardiogram can have obvious ischemic changes during angina attack: (3) patients with mild to moderate anxiety who met the diagnostic criteria of anxiety and scored between 14 and 29 (4) Conforming to the diagnostic criteria of chest stuffiness, pain and depression in traditional Chinese medicine: (5) Conforming to the syndrome differentiation criteria of collateral-qi stagnation syndrome type: (6) Stable vital signs and certain expressive ability: (7) 30 years old = age =75 years old, male or female: (8) Those who have not taken other anti-anxiety drugs within 2 weeks: (9) patients who signed the informed consent form. Patients who met all nine of these criteria were eligible for the study.
Exclusion criteria
Exclusion criteria: (1) Chest pain caused by acute myocardial infarction, unstable angina, other heart diseases, hyperthyroidism, biliary heart disease, climacteric syndrome, gastric and esophageal reflux, neurosis, etc. :(2) with uncontrolled grade III hypertension (systolic blood pressure 180m and/or diastolic blood pressure 2110mHg), severe cardiopulmonary dysfunction; (3) patients with other clinical conditions that may increase the risk of bleeding, such as the history of bleeding in important organs (such as cerebral hemorrhage, upper gastrointestinal bleeding, etc.), abnormal coagulation function, and recent active bleeding, etc. (4) patients with severe liver and kidney insufficiency; Patients with progressive developmental diseases or diseases with very poor prognosis such as severe infections, severe water and electrolyte disorders, acid-base disorders: (5) Patients with cardiac function class IV: (6) Severe anxiety requiring oral anti-anxiety medication, HAMA score 29: (7) Pregnant and lactating women: (8) Susceptible to drug allergy: (9) those who were deemed unsuitable for clinical trial participation by the investigators. Patients with any of the above criteria were excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seattle Angina Scale score;Hamilton Anxiety Scale score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Electrocardiogram;TCM syndrome score; | — |
Countries
China
Contacts
Public ContactZhao Mingjun
Affiliated Hospital of Shaanxi University of Chinese Medicine
Outcome results
None listed